Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
ZUG, Switzerland, Feb. 2, 2017 -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will provide a business update tomorrow, Friday, Feb. 3, 2017. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the update.
To participate in this conference call, dial 1-877-280-3488 (USA) or +1-646-254-3374 (International), and enter passcode 5782790. A live webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Company contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 13 50, [email protected]
Media contact: David Schull, Russo Partners, 1-858-717-2310, [email protected]
